Abstract. Fibronectin (FN) has been recognized as the key element in promoting cell adhesion, migration and oncogenic transformation. αvβ6 integrin binds with FN in an RGD-dependent manner and is associated with invasion and poor prognosis in many types of cancers. The extracellular matrix (ECM) is commonly degraded and becomes disorganized in cancers. Previous studies have shown that FN can be degraded into fragments by MMP-9 in vitro; MMP-9 expression is upregulated in breast cancer, therefore, the role of degraded FN in breast cancer progression needs to be investigated. In the present study, expression of β6 integrin in breast cancer tissues was analyzed. The data were quite consistent with the hypothesis that β6 integrin expression is an indicator of poor prognosis. Cell surface expression of β6 integrin was correlated with the invasive behavior of the breast cancer cell lines. MMP-9-degraded FN was used to explore its effects on cell invasion and expression of β6 integrin. The results indicated that MMP-9-degraded FN can adjust constituents of the αvβ6 heterodimers at the early phase and significantly elevate amounts of β6 integrin subunits at a later period. To better elucidate the mechanism by which β6 integrin regulates FN-induced cell migration and invasion, we determined the expression and activity of the downstream kinases of β6 integrin, and elucidated that focal adhesion kinase (FAK)-Src interaction promoted the invasion and migration of breast cancer cells after treatment of MMP-9-degraded FN through the Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways.
Introduction
Numerous studies have shown that integrin expression profiles are subject to change during cancer growth and progression, and these changes contribute to the aggressive behavior of cancer cells (1, 2) . Notably, integrins also play important roles in the tumor microenvironment and significantly contribute to tumor progression (3) . The αvβ6 integrin is an epithelial restricted transmembrane protein and is upregulated in many tumor types, including pancreatic ductal cancer, head and neck squamous cell cancer, ovarian cancer, colon cancer, cholangiocarcinoma and cervical cancer (4, 5) . Enhanced expression of this integrin is associated with poor prognosis in colon cancer and oral cancer (4, 6) . However, the role of αvβ6 integrin in breast carcinoma is still controversial.
Integrins bind to extracellular matrix (ECM) glycoproteins including collagens, fibronectins (FNs), laminin, and control biological and cellular functions such as cell adhesion, migration, invasion, proliferation, differentiation and apoptosis (4) . αvβ6 integrin binds FN in an RGD-dependent manner (7) . FN has been implicated in the development of multiple types of human cancer (8, 9) and is associated with cell migration and invasion in metastatic models (9, 10) . In breast cancer, FN has shown higher expression than that in normal breast parenchyma, with a different distribution (11) .
Molecules of the ECM can be degraded by proteolytic enzymes, such as matrix metalloproteinases (MMPs) (12) . Degradation of ECM is precisely regulated under normal physiological conditions, but when dysregulated it causes many diseases such as cancer, arthritis, and fibrosis (13) . MMP-9 expression is often upregulated and the upregulation is associated with a shortened relapse-free survival in breast cancer patients (14) . Previous studies have shown that FN can be degraded into fragments in vitro by MMP-9 (15); therefore, the role of degraded FN in breast cancer progression should be clarified.
Here, we examined the expression of β6 integrin using immunohistochemistry in breast cancer samples, investigated its correlation with clinicopathological disease variables and evaluated its prognostic value. Furthermore, we assessed the influence of MMP-9-degreaded FN on the regulation of β6 integrin and breast cancer progression by incubating MCF-7 human breast cancer cells with MMP-9-degraded FN. Invasion assay. Cell invasion through a three-dimensional ECM was assessed using BD Matrigel invasion chambers (BD Biosciences, Bedford, MA, uSA). Transwell membranes were coated with 50 µg/ml human cellular FN or MMP-9-degraded FN as previously described (18) . Cells were resuspended and plated into the chamber inserts. For antibodyblockage studies, the cells were seeded in medium containing anti-β6 integrin. After 24 h, the cells invading the filters were fixed, stained, and counted. At least 3 separate microscopic fields were counted per membrane.
Materials and methods

Ethics
Immunohistochemistry. The standard avidin-biotin indirect immunoperoxidase method was adopted for immunohistochemistry using routinely processed paraffin-embedded specimens. The sections were incubated with the primary antibodies overnight at 4˚C, and then incubated with biotinylated secondary antibodies and the avidin-peroxidase complex. The peroxidase reaction was visualized by incubation with DAB.
Immunofluorescence. For immunofluorescence staining, a total of 2x10 4 cells were plated onto glass coverslips and grown for 48 h before fixation with 4% paraformaldehyde. Cells were permeabilized with 0.25% Triton X-100. Slides were then stained with fluorescein-conjugated secondary Ab for 30 min at 25˚C after incubation with the primary antibody. Hoechst 33258 dye (1 µg/ml; Sigma) was subsequently used to stain the nuclei.
Flow cytometry. Confluent cells (80%) were harvested and resuspended in HEPES buffer. Cells were incubated with mouse antibody against human β6 integrin. After 30 min at 4˚C, the cells were washed and stained with a R-phycoerythrin-labeled goat anti-mouse-IgG [F(ab)2-fragment; Dianova]. Flow cytometry was performed using a FACSCalibur system (Becton-Dickinson, Heidelberg, Germany).
Isolation of tumor cell variants.
Tumor cell variants with high and low β6 integrin expression were isolated from the parental MCF-7 breast cancer cells using a cell sorter. Single cells were plated into 96-well plates and expanded. The expression of β6 integrin was measured by flow cytometry. Repeated measurements of the cell surface expression of β6 integrin confirmed that the stability of the β6 integrin expression phenotype of the subcell lines remained for at least 50 generations.
Immunoprecipitation analysis. For immunoprecipitation in vitro, the MMP-9-degraded FN and cell lysate of MCF-7 were mixed in binding buffer. Immunoprecipitations were carried out indirectly using anti-β3 and -β5 (B-10) (both from Santa Cruz Biotechnology), β6 integrin or isotype-matched control IgG (Sigma) and captured with protein G agarose beads (Thermo Fisher Scientific Inc., Rockford, IL, USA). Extracts and precipitates were analyzed by western blotting.
Western blot analysis. Samples (30 µg) of the cellular proteins were loaded on 12% SDS-polyacrylamide gel. Separated proteins were transferred to PvDF membranes. The membranes were incubated with primary antibodies, followed by secondary antibodies (Maxim Biotechnology, Fuzhou, China). Detection was performed using ECL chemoluminescence (ECL System; Amersham International, Little Chalfont, uK). β-actin was used as the control (diluted 1:1,000; Chemicon, Temecula, CA, uSA). The membranes were scanned and the intensity of the bands were analyzed using Gel-Pro analyzer software.
Statistical analysis. SPSS v20.0 was used for statistical analysis. Student's t-test was used to determine the significance of two groups, respectively. Spearman's correlation was used to identify the correlation between the expression of β6 integrin and invasive cell number. P<0.05 was considered to indicate statistically significant differences.
Results
β6 integrin is highly correlated with the prognosis of breast cancer patients. Expression of β6 integrin in breast cancer tissues was analyzed by immunohistochemical staining (score 0, no expression; 1, low expression; 2, high expression) (Fig. 1Aa-d) . Kaplan-Meier plot is shown in Fig. 1B .
There was prominent survival difference between groups with score 0 and score 2 (P=0.092), as well as a survival difference in patients with score 1 and score 2 (P=0.073) as determined by the log-rank test. Furthermore, the Kaplan-Meier plot indicated that patients with score 0 or 1 had a longer survival period than patients with score 2 .
Invasive cancer cells display high β6 integrin expression.
Cell invasiveness of 6 breast cancer cell lines and MCF-10A was determined by the matrix invasion assay. The invasiveness of each cell line was quantified as the invasive cell number (Fig. 1D) . Expression of β6 integrin in these cell lines was evaluated by qPCR (Fig. 1C) . We presented a logistic regression-based method for identifying the relation- ship between expression of β6 integrin and invasive cell number and there was significant linear relationship (Fig. 1E , r 2 =0.7413).
High β6 integrin expression leads to enhanced cell invasion.
MCF-7/β6 integrin cells exhibited a much higher fluorescence intensity (data not shown). Western blotting revealed that the difference in the expression of β6 integrin was 4.3-fold between these two cell lines ( Fig. 2A) . The cell invasiveness of the MCF-7/β6 integrin cells was higher than that of cells transfected with the pcDNA plasmids (Fig. 2B) . We next isolated two subcell lines that expressed either high or low amounts of β6 integrin from MCF-7 cells using a cell sorter. The stable β6 integrin expression levels were confirmed during culture by cytofluorometry (data not shown). β6 integrin expression of the isolated β6 high subcell line was significantly increased to >7.3 times the value of the β6 low group as shown by western blotting ( Fig. 2A) . Results of the invasion assay revealed that the invasiveness of the β6 high group was markedly higher than that of the β6 low group (Fig. 2B) .
MMP-9-dFN treatment upregulates β6 expression. MMP-9
was localized in the front breast cancer cells (Fig. 3A) . Activated MMP-9 was incubated with plasma FN. After 48 h, a clear band was visible at the level of 120 kDa (Fig. 3B) . A significant increase in β6 integrin mRNA was observed in the MMP-9-dFN and the MMP-9-dFN/TGF-β1-treated cells, whereas the native FN group also showed a similar tendency but not as conspicuous (Fig. 3C) . Immunoblotting demonstrated that the protein levels of β6 integrin subunit were also increased significantly after TGF-β1 treatment and more prominent following treatment with the combination of MMP-9-dFN/TGF-β1. Expression of β6 integrin after the combined treatment with MMP-9-dFN/TGF-β1 was significantly increased to >2-fold of the value of the TGF-β1-treated group, and 4-fold of the MMP-9-dFN-treated group (Fig. 3D ).
αvβ6 integrin heterodimers form following disruption of heterodimers of αvβ3 and αvβ5 by MMP-9-dFN.
Immunofluorescence of the β6 integrin subunits in MCF-7 cells showed patchy staining of bottom surfaces of cell clusters at the cell peripheries (Fig. 3E) . After FN treatment, the staining appeared in larger adhesion plaques of the spreading cells, and was intensely positive in larger adhesion plaques after treatment with MMP-9-dFN (Fig. 3E) . Immunoprecipitation revealed enhanced levels of β6 integrin heterodimers co-precipitating with the αv subunit in the MMP-9-degraded FN-treated cells with depressed β3 and β5 integrin, whereas FN could not regulate the αvβ6 integrin heterodimers (Fig. 3F) .
Promotion of the migration and invasion of MCF-7 cells by MMP-9-dFN through FAK phosphorylation.
The MCF-7 cells were significantly more chemotactic when the Transwells were coated with MMP-9-degraded FN than when they were not coated or were coated with FN (Fig. 4A) . MMP-9-dFN-mediated migration was inhibited by a function blocking β6 integrin antibody. Transient knockdown of FAK by specific siRNA in the MCF-7 cells blocked invasion induced by MMP-9-dFN (Fig. 4A) . Western blotting of the cell lysates revealed high expression levels of pFAK Ser732 and pFAK Ser722 in the MMP-9-degraded FN-treated cells (Fig. 4B) . FAK was found to be phosphorylated on Thr567/577 in both the MMP-9-dFN-and FN-treated cells (Fig. 4B) . Inhibition of Src by PP2 blocked the phosphorylation of FAK at its Ser732, Ser722, and Tyr576 residues (Fig. 4C ) and cell invasion induced by MMP-9-dFN (Fig. 4D) .
MMP-9-dFN induces MCF-7 migration and invasion through crosstalk with FAK-Src, Src-related Erk and
PI3K/Akt/Smad-1/5/8 activation. MCF-7 cells treated with MMP-9-dFN displayed elevated phosphorylation of Src, Erk1/2, and PI3K/Akt in a dose-dependent manner (Fig. 5A ).
As shown in Fig. 5B , FAK-associated phosphorylation of Src, Erk1/2 and PI3K/Akt was reduced in the FAK-knockdown cells. LY294002 (PI3K inhibitor) markedly lowered the phospho-Smad-1/5/8 protein modulated by MMP-9-dFN, and reduced phospho-Smad-1/5/8 staining in the nucleus. However, PD98059 (Erk pathway inhibitor) did not significantly change the expression of phospho-Smad-1/5/8 and the nuclear distribution ( Fig. 5C and D) .
Discussion
Breast cancer is commonly associated with marked alteration in ECM architecture and composition, especially in ECM proteins functioning as ligands (19, 20) . Knowledge of how ECM composition and topography are maintained and how ECM deregulation influences cancer progression may help develop new therapeutic interventions by targeting the tumor niche. Among the ECM components, FN has been recognized as a key element in promoting cell adhesion and migration of many cell types. In fact, FN has been implicated in the metastatic phenotype of multiple types of human cancers (9) , and it is also associated with cell migration and invasion in several metastatic models (10, 21) . FN in breast carcinomas has stronger expression than that in normal breast parenchyma, with a different distribution (22) . Abnormal ECM affects cancer progression by directly promoting cellular transformation and metastasis (23) . Confocal scanning laser microscopy revealed that co-labeled patterns of MMP-9 with FN and the interaction between MMP-9 and FN contribute to FN degradation (24) . Our experiments also showed that MMP-9 localized to the cytoplasm of the front cancer cells, suggesting that MMP-9 produced by cancer cells has contact with FN distributed in the stroma leading to FN degradation. Thus, it was hypothesized that MMP-9 cleaves FN and contributed to the migration and progression of breast cancer. In this study, MCF-7 cells were significantly more chemotactic when the Transwell plates were coated with MMP-9-degraded FN than when they were not coated or coated with FN.
Interactions between FN and integrins play an important role in tumor cell migration, invasion and metastasis (25) . αvβ6 integrin was found to be significantly upregulated in certain cancer types including colon (18, 26) and ovarian carcinoma (27) and in early stage non-small cell lung cancer (NSCLC) (28) . In the present study, β6 integrin expression was upregulated in many breast cancer samples and high expression of β6 integrin was found to be associated with poor prognosis. Expression of β6 integrin in several breast cancer cell lines was also determined by immunoblotting. A significant linear relationship between invasive cell number and relative expression of β6 integrin was established.
αvβ6 integrin was found to enhance the tumorigenic features of colon carcinoma, including activation of autocrine TGF-β and migration on interstitial FN. After MMP-9-degraded FN treatment, the staining of β6 integrin was intensely positive in larger adhesion plaques of spreading cells. Furthermore, a marked inductive formation of αvβ6 integrin heterodimers occurred during treatment of MMP-9-degraded FN at the expense of disrupting heterodimers of αvβ3 and αvβ5 integrin. These results indicate that MMP-9-degraded FN may adjust components of the αv heterodimers.
FAK, a cytoplasmic non-receptor tyrosine kinase signaling protein, has recently been established as a key component of the signal transduction pathway triggered by interaction with β integrin. Our results showed high expression levels of pFAK Ser732, pFAK Ser722, and pFAK Tyr576 after treatment with MMP-9-degraded FN. Phosphorylation of FAK at its Ser732, Ser722, Tyr576 residues induced by MMP-9-degraded FN was obviously reduced upon treatment with the Src inhibitor. The signaling pathways downstream of FAK are complex and roughly divided into the FAK-Src-related Ras-MEK-MAPK and PI3K/Akt signaling pathways. It appears that FAK promotes FN-mediated cancer metastasis through the activation of Src, Erk1/2 and PI3K/Akt. In the present study, It has been established that activation of integrins and cell signaling through PI3K/Akt are followed by the phosphorylation of signal transducer Smad-1/5/8 and the regulation of target genes (29) . The phosphorylated Smad1 and Smad5 form heterooligomeric complexes with Smad4 and then translocate into the nucleus to activate the transcription of target genes (30) . After the treatment of MMP-9-degraded FN, intensive phospho-Smad-1/5/8 staining was observed. In addition, phospho-Smad-1/5/8 was markedly weakened when PI3K was inhibited. In brief, those results indicate that phospho-Smad-1/5/8 induced by MMP-9-degraded FN was PI3K/Akt-dependent.
In conclusion, we report that the protein expression profile of β6 integrin is statistically correlated with the poor prognosis of breast cancer patients. The present study demonstrated that MMP-9-degraded FN promoted the invasion and migration of breast cancer through interaction with αvβ6 involving the crosstalk between FAK-Src and Src-regulated Erk1/2 and PI3K/Akt/Smad-1/5/8 signaling. Since elevated β6 integrin expression is predictive of outcome in early-stage breast cancer, the choice of an optimal integrin ligand is an aspect of paramount importance in the design of integrin-based targeted therapies for breast cancer.
